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ABSTRACT 
The aim of this work was to develop and validate a simple estimation method of Zileuton in bulk powder and tablet using UV spectrophotometric method. The 
method was developed using methanol as a solvent and absorbance was measured at 229nm. Beers law was obeyed in the concentration range of 1-10µg/ml. 
Calibration curve shows a linear relationship between the absorbance and concentration. The line equation y=0.1045x + 0.0189 with r
2 of 0.9994 was obtained. 
The method was validated as per ICH guidelines. Simple, accurate and cost efficient spectrophotometric method has been developed for the estimation of 
Zileuton in bulk powder and tablet dosage form. 
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INTRODUCTION 
Zileuton is an orally active 5-lipoxygenase inhibitor that is 
being  investigated  in  the  treatment  of  ulcerative  colitis.  It 
may also have a role in the treatment of asthma and allergic 
rhinitis. IUPAC name of the Zileuton is N-[1-benzo (b) thien-
2-ylethyl]-N-hydroxyurea. It is official in USP 
1. It is listed in 
the  Martindale  the  complete  drug  reference 
2  and  Merck 
index 
3. 
Zileuton is used for the prophylaxis and chronic treatment of 
asthma in adults and children 12 years of age and older 
4. 
Contraindications  are  active  liver  disease  or  resistant 
elevation  in  transaminase  at  least  3  times  the  history  of 
allergic  reactions  to  Zileuton  or  any  of  its  inactive  
ingredients 
5.  Zileuton  is  a  minor  substrate  of  CYP1A2, 
2C8/9, 3A4, and a weak inhibitor of CYP 1A2. The drug has 
been shown to increase the serum concentration or effects of 
theophylline, propranolol and warfarin, although significant 
increase in prothrombin time is not obvious. It is advised that 
the doses of  each medication be monitored and/or reduced 
accordingly 
6. 
Extensive literature survey revealed that the determination of 
Zileuton  and  its  inactive  N-dehydroxylated  metabolite  in 
plasma by HPLC 
7 and LC-MS/MS method in plasma 
8 were 
reported. However there is no evidence for the estimation of 
Zileuton  by  UV  spectrophotometry  in  bulk  and  in  tablet 
formulation. So, an attempt was made to develop simple, cost 
effective and accurate UV spectrophotometric method for the 
estimation of Zileuton in bulk and in tablet formulation and 
to validate the developed method. 
 
MATERIALS AND METHODS 
Materials 
Zileuton  raw  material  was  procured  from  AUROBINDO 
PHARMA  LTD.,  Hyderabad,  India.  Tablet  formulation 
GRILUTO-CR  (Cadila  Healthcare  Limited,  Goa,  India) 
containing  Zileuton  600  mg  was  purchased  from  local 
pharmacy.  All  reagents  and  solvents  used  were  analytical 
grade.  Ultra-pure  water  was  obtained  from  a  water 
purification unit. 
Instrumentation  
UV  spectrophotometric  method  was  performed  on 
LABINDIA  UV-3000
+  Double  Beam  UV-Visible  Ratio-
Recording Scanning Spectrophotometer with pair of 10 mm 
matched quartz cell. 
Selection of solvent   
Different  solvents  such  as  distilled  water,  methanol, 
acetonitrile, chloroform, diethyl ether and acetone were tried 
for estimation of Zileuton in tablet dosage form. Maximum 
sensitivity was found with Methanol. Hence, Methanol was 
selected as a solvent for study. 
Preparation of standard stock solution 
25  mg  of  Zileuton  standard  substance  was  weighed  and 
transferred into 25 ml volumetric flask separately, dissolved 
in methanol and made up to the volume with methanol. This 
solution contains 1mg/ ml concentration.  
Selection  of  wavelength  for  estimation  and  stability 
studies 
The standard stock solution was further diluted with distilled 
water to get the concentration of 10 µg/ml and the solution 
was scanned between 200 - 400 nm using distilled water as 
blank. From the spectra, λmax was found to be 229 nm and 
was  selected  as  analytical  wavelength.  The  stability  was 
performed  by  measuring  the  solution  at  different  time 
intervals. It was observed that Zileuton in distilled water was 
stable up to 4 hours at the selected wavelength. 
Preparation of calibration graph 
Working standard solution was prepared by pipetting 5 ml of 
the standard stock solution into a 25 ml volumetric flask and 
made  up  to  the  volume  with  distilled  water  to  get  the 
concentration of 200 µg/ ml. 0.5 – 5 ml were transferred into 
a  series  of  100  ml  volumetric  flasks  and  made  up  to  the 
volume  with  distilled  water.  The  absorbance  of  different 
concentration  solutions  were  measured  at  229  nm.  The 
calibration curve  was constructed by plotting concentration 
Vs  absorbance.  Zileuton  was  linear  with  the  concentration 
range of 1 - 10 µg/ ml at 229 nm. 
Quantification of raw material 
2.0 ml of working standard solution was taken into a series of 
six 100 ml volumetric flasks and the volume was made up to 
mark with distilled water. The absorbance of these solutions 
was measured at 229 nm. The amount of Zileuton present in 
the raw material was determined by using slope and intercept 
values from calibration graph.   
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Assay of tablet formulation 
Ten  tablets  of  formulation  (GRILUTO-CR  containing  600 
mg  of  Zileuton)  were  weighed  accurately  and  the  average 
weight of each tablet was found. The tablets were ground to a 
fine  powder.  The  tablet  powder  equivalent  to  25  mg  of 
Zileuton was weighed and transferred into 25 ml volumetric 
flask.  Added  about  20  ml  of  methanol  to  dissolve  the 
substance  and  the  solution  was  sonicated  for  15  minutes. 
Then it was made up to the volume to 25 ml with methanol (1 
mg/  ml)  and  centrifuged  for  15  minutes.  The  supernatant 
liquid  was  filtered  through  Whatmann  filter paper  No.  41. 
From  the  clear  solution,  further  dilutions  were  made  by 
diluting  5  ml  into  25  ml  with  distilled  water.  2  ml  was 
pipetted out into a series of six 100 ml volumetric flasks and 
made  up  to  the  mark  with  distilled  water  to  get  the 
concentration  of  4  µg/  ml  of  Zileuton,  theoretically.  The 
absorbances of six replicates were measured and the amount 
was calculated by using regression equation. This procedure 
was repeated for six times. 
VALIDATION  OF  UV  SPECTROPHOTOMETRIC 
METHOD  
Linearity and range 
Ability  of the method to elicit test results that are directly 
proportional to the concentration of analyte. The linearity was 
determined by analyzing 6 independent levels of calibration 
curve in the range of 1– 10 µg/ ml at 229 nm. A calibration 
curve was plotted between concentration and absorbance and 
correlation  coefficient  and  regression  line  equation  for 
Zileuton were determined. 
Precision 
Precision may be defined as the concordance of a series of 
measurement of the same quantity. Intra-day precision was 
determined  by  analyzing  Zileuton  at  three  different  time 
points  of  the  same  day  and  inter-day  precision  was 
determined by analyzing Zileuton three different time points 
on different days and %RSD was calculated.  
Accuracy  
It  means  the  concordance  between  it  and  true  or  most 
probable  value.  Accuracy  was  determined  by  performing 
recovery studies by spiking different concentrations of pure 
drug in the pre-analyzed powder for infusion sample within 
the analytical concentration range of the proposed method at 
three  different  set  at  level  of  80%,  100%  and  120%.The 
amount  of  Zileuton  was  calculated  at  each  level  and  % 
recovery were computed.  
LOD and LOQ 
The  LOD  and  LOQ  were  estimated  from  the  set  of  6 
calibration curves used to determine method linearity. 
LOD=3.3σ/S and LOQ=10σ/S 
Where,  σ  =  the  standard  deviation  of  y-intercepts  of 
regression lines 
S = the slope of the calibration curve 
 
Table 1: Optical characteristics of Zileuton 
Parameters  Results 
λ max (nm)  229 
Beer’s Law Limit (µg/ ml)  1 – 10 
Sandell’s sensitivity 
(g/cm
2/0.001 A.U) 
0.00957 
Molar absorptivity 
(L mol
–1 cm
–1) 
2.5138×10
4 
Correlation coefficient (r)  0.9994 
Regression equation 
(y=mx+c) 
Y = 0.1045x + 0.0189 
Slope(m)  0.1045 
Intercept(c)  0.0189 
LOD  0.1890 µg/ml 
LOQ  0.5728 µg/ml 
Standard error  0.0003 
 
 
Table 2: Quantification of raw material 
Drug  Amount found (µg/ml)*  Percentage Obtained* (%)  Mean (%)  SD  %RSD  SE 
 
 
 
 
 
Zileuton 
3.9820  99.55   
100.51 
 
 
 
 
 
1.0728 
 
1.0674 
 
0.0298  4.0570  101.42 
3.9676  99.19 
4.0187  100.47 
4.0793  101.98 
4.0187  100.47 
*Mean of six observations 
 
Table 3: Quantification of formulation 
Drug  Labelled amount 
(mg/tab) 
Amount found 
(mg/tab) 
Percentage Obtained*   % Mean 
 
SD  % RSD  SE 
 
 
 
Zileuton 
600.0  588.70  98.11   
 
 
 
 
99.38 
 
 
 
 
 
1.2778 
 
 
 
 
 
1.2857 
 
 
 
 
 
0.0355 
600.0  600.48  100.58 
600.0  588.61  98.10 
600.0  607.06  101.18 
600.0  596.54  99.42 
600.0  593.39  98.90 
*Mean of six observation 
 
Table 4: Intraday and interday analysis of formulation 
Drug  Condition  Labelled amount 
(mg/tab) 
Amount found 
(mg/tab)* 
Percentage 
Obtained* 
Average (%)  S.D  % R.S.D  S.E 
 
Zileuton 
 
Intraday  600 
600 
600 
599.42 
603.77 
596.74 
99.90 
100.63 
99.46 
 
100.00 
 
0.5910 
 
0.5910 
 
0.0657 
Zileuton  Interday  600 
600 
600 
603.44 
595.16 
607.51 
100.57 
99.28 
101.25 
 
100.37 
 
1.0006 
 
0.9970 
 
0.1112 
*Mean of three observations 
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Table 5: Recovery Study 
Drug  Level 
(%) 
Drug added 
(µg/ml) 
Drug recovered 
(µg/ml) 
%  Recovery ± S.D  %R.S.D 
Zileuton  80  3.2350  3.2459  100.33±0.4854  0.4839 
100  4.0532  4.0691  100.39±0.4631  0.4613 
120  4.8480  4.8574  100.19±0.2815  0.2809 
*Mean of three observations 
 
 
Figure 1: Chemical structure of Zileuton 
 
Figure 2: UV spectrum of Zileuton 
 
 
Figure 3: Calibration curve of Zileuton 
 
RESULTS  
Linearity 
The linearity of Zileuton was found to be in the range of 1 - 
10  µg/  ml.  with  correlation  coefficient  0.9994.  Calibration 
curve is shown in Fig.3. Optical characteristics were shown 
in Table 1. 
Precision 
The percentage of Zileuton present in the prepared raw material 
solution  was  found  to  be  100.51%  ±  1.0728  (Table  2).  The 
percentage  label  claim  present  in  the  tablet  formulation 
(GRILUTO-CR) was found to be 99.38% ± 1.2778 of Zileuton. 
The  precision  of  the  method  was  confirmed  by  the  repeated 
analysis of  formulation. The %RSD  was  found to be 1.2857 
(Table 3).  
Precision of the method was confirmed by intraday and inter 
day  analysis.  The  percentage  RSD  value  of  the  intraday  and 
inter day analysis  of Zileuton was  found to be 0.5910% and 
0.9970%, respectively (Table 4).  
Accuracy 
Accuracy of the method was confirmed by recovery study from 
marketed  formulation  at  three  level  of  standard  addition.  % 
Recovery for Zileuton was found to 100.19 - 100.39 (Table 5). K. Anandakumar et al. IRJP 2012, 3 (12) 
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Limit of detection and limit of quantification 
LOD and LOQ were found to be 0.1890 µg/ml and 0.5728 
µg/ml, respectively. 
 
DISCUSSION 
The  proposed  method  for  the  determination  of  Zileuton  in 
solid dosage form was found to be precise, selective, rapid 
and economical. Zileuton exhibited maximum absorption at 
229 nm and obeyed Beer’s law in the concentration range of 
1 - 10 µg/ ml. The proposed method for the determination of 
Zileuton showed linear regression Y = 0.1045x + 0.0189 with 
correlation  coefficient  (R2)  of  0.9994  (Figure  2).  The 
percentage RSD for analysis of formulation was found to be 
within the limit. 
Our  studies  revealed  a  recovery  percentage  of  100.19  - 
100.39%,  which  indicates  that  the  developed  method  was 
found to be accurate. The proposed methods can be used for 
the  drug  analysis  in  routine  quality  control  and  method 
proves to be more economical.  
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